Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SCHOTT to Strengthen Pharmaceutical Site in Hungary

Published: Monday, June 10, 2013
Last Updated: Sunday, June 09, 2013
Bookmark and Share
New maintenance facility will be opened in the Lukácsháza region.

SCHOTT Pharmaceutical Systems has announced plans to significantly expand its Hungarian site Lukácsháza that manufactures pharmaceutical primary packaging.

Investments in the mid-double-digit million euro range are planned from now until 2016.

The first step will be to open a new maintenance facility for overhauling and upgrading production machines that will create more than 30 new jobs in the Lukácsháza region.

In addition, production capacity should continue to increase in Hungary over the next few years.

SCHOTT manufactures ampoules, vials, and cartridges or so-called primary packaging for the pharmaceutical industry at its site in Lukácsháza near the Hungarian-Austrian border. The plant has continued to grow since it first opened in 1993.

Today, Lukácsháza, with its roughly 530 employees and annual production of more than 1.7 billion units, is the SCHOTT Pharmaceutical Division's single largest site.

The products manufactured in Lukácsháza are mainly exported to all parts of Europe and overseas, but also produced for the local market.

In addition to opening this global maintenance center, SCHOTT has also established a team of experts at this site that will overhaul its production machines on a regular basis and upgrade them to meet the latest technical standards.

“By doing so, we actively demonstrate our commitment to living up to the highest standards for quality and maintaining these over the long-term, in fact even for all of our global plants,” explains Dr. Jürgen Sackhoff, Vice President of SCHOTT Pharmaceutical Systems.

For Dr. Frank Heinricht, Chairman of the Board of Management, the expansion of the site in Hungary is only part of what can be considered a global investment strategy. After all, SCHOTT also intends to install new production lines in Hungary over time.

“On average, our annual production of ampoules, cartridges and vials will increase by almost half at this site,” Heinricht says and adds, “With our investment strategy, we will be helping our customers around the world to meet their quality and growth targets.”

The company also opened a new plant in India just recently and significantly expanded its capacities in Indonesia and Russia. A new joint venture in China also further expands its global manufacturing network.

Strong base in the region

SCHOTT’s expansion in Hungary also sends a powerful message to the Lukácsháza region. “We are aware of our importance as a local employer,” explains Christoph Döppes, Managing Director of the site in Lukácsháza.

“Our commitment here is long-term in nature and we are working together with the local authorities on further developing this site,” he adds.

Besides opening its new machine building facility, which received public funding support, and expanding its production capacities, SCHOTT also plans to create a number of new skilled jobs for machine builders, technicians and engineers, for instance.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCHOTT Committed to Further Investments in Brazilian Pharma Packaging Plant
Celebrating 80 years of ampoule manufacturing in Brazil.
Thursday, April 23, 2015
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!